keyword
MENU ▼
Read by QxMD icon Read
search

ASCVD risk

keyword
https://www.readbyqxmd.com/read/28330662/pericardial-but-not-hepatic-fat-by-ct-is-associated-with-cv-outcomes-and%C3%A2-structure-the-multi-ethnic-study-of-atherosclerosis
#1
Ravi V Shah, Amanda Anderson, Jingzhong Ding, Matthew Budoff, Oliver Rider, Steffen E Petersen, Majken Karoline Jensen, Manja Koch, Matthew Allison, Nadine Kawel-Boehm, Jessica Wisocky, Michael Jerosch-Herold, Kenneth Mukamal, Joao A C Lima, Venkatesh L Murthy
OBJECTIVES: The study sought to determine the associations between local (pericardial) fat and incident cardiovascular disease (CVD) events and cardiac remodeling independent of markers of overall adiposity. BACKGROUND: The impact of pericardial fat-a local fat depot encasing the heart-on myocardial function and long-term CV prognosis independent of systemic consequences of adiposity or hepatic fat is an area of active debate. METHODS: We studied 4,234 participants enrolled in the MESA (Multi-Ethnic Study of Atherosclerosis) study with concomitant cardiac magnetic resonance imaging and computed tomography (CT) measurements for pericardial fat volume and hepatic attenuation (a measure of liver fat)...
March 10, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28330658/nonobstructive-coronary-artery-disease-by-coronary-ct-angiography-improves%C3%A2-risk-stratification-and-allocation%C3%A2-of-statin%C3%A2-therapy
#2
Hamed Emami, Richard A P Takx, Thomas Mayrhofer, Sumbal Janjua, Jakob Park, Amit Pursnani, Ahmed Tawakol, Michael T Lu, Maros Ferencik, Udo Hoffmann
OBJECTIVES: This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA). BACKGROUND: Detection of nonobstructive CAD by coronary computed tomography angiography may improve risk stratification and permit individualized and more appropriate allocation of statin therapy...
March 10, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28325797/management-of-atherosclerotic-cardiovascular-disease-risk-factors-in-the-older-adult-patient-with-diabetes
#3
Mary T Korytkowski, Daniel E Forman
: Older adults with diabetes are at higher risk for atherosclerotic cardiovascular disease (ASCVD) than younger adults with diabetes and older adults without diabetes. The rationale to implement ASCVD risk-lowering therapies in older adults with diabetes is compelling. Recommendations for lifestyle modification, lipid-lowering therapy, blood pressure management, blood glucose control, and aspirin therapy are often based on studies that show their efficacy in younger populations. However, the risks associated with each of these interventions increase with age, and favorable risk-to-benefit ratios demonstrated in younger adults with diabetes are less certain in older populations...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28323928/physical-activity-vitamin-d-and-incident-atherosclerotic-cardiovascular-disease-in-whites-and-blacks-the-aric-study
#4
Kathleen Chin, Di Zhao, Martin Tibuakuu, Seth S Martin, Chiadi E Ndumele, Roberta Florido, B Gwen Windham, Eliseo Guallar, Pamela L Lutsey, Erin D Michos
Context: Physical activity (PA) is associated with 25-hydroxyvitamin D [25(OH)D] levels. Both are associated with atherosclerotic cardiovascular disease (ASCVD), but their joint association with ASCVD risk is unknown. Objective: To examine the dose-response between PA and 25(OH)D, and to assess effect modification of 25(OH)D and PA with ASCVD risk. Design: Cross-sectional and prospective study using Poisson and linear regression. Setting: Community-dwelling Atherosclerosis Risk in Communities cohort...
February 17, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28315622/subclinical-atherosclerosis-statin-eligibility-and-outcomes-in-african-american-individuals-the-jackson-heart-study
#5
Ravi V Shah, Aferdita Spahillari, Stanford Mwasongwe, J Jeffrey Carr, James G Terry, Robert J Mentz, Daniel Addison, Udo Hoffmann, Jared Reis, Jane E Freedman, Joao A C Lima, Adolfo Correa, Venkatesh L Murthy
Importance: Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our knowledge, in large African American populations. Objective: To compare the relative accuracy of US Preventive Services Task Force (USPSTF) and American College of Cardiology/American Heart Association (ACC/AHA) recommendations in identifying African American individuals with subclinical and clinical atherosclerotic cardiovascular disease (ASCVD)...
March 18, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28314800/performance-of-the-atherosclerotic-cardiovascular-disease-pooled-cohort-risk-equations-by-social-deprivation-status
#6
Lisandro D Colantonio, Joshua S Richman, April P Carson, Donald M Lloyd-Jones, George Howard, Luqin Deng, Virginia J Howard, Monika M Safford, Paul Muntner, David C Goff
BACKGROUND: The atherosclerosis cardiovascular disease (ASCVD) Pooled Cohort risk equations have shown different calibration across US populations with varied levels of social deprivation. METHODS AND RESULTS: We analyzed the calibration and discrimination of the Pooled Cohort risk equations by social deprivation status among 9066 REGARDS (REasons for Geographic And Racial Differences in Stroke) study participants not taking statins for whom ASCVD risk may lead to statin initiation...
March 17, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28314797/effect-of-2013-acc-aha-blood-cholesterol-guidelines-on-statin-treatment-patterns-and-low-density-lipoprotein-cholesterol-in-atherosclerotic-cardiovascular-disease-patients
#7
Ted Okerson, Jeetvan Patel, Stefan DiMario, Tanya Burton, Jerald Seare, David J Harrison
BACKGROUND: Preceding release of the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guidelines, prescribers aimed for specific low-density lipoprotein cholesterol (LDL-C) goals in patients with atherosclerotic cardiovascular disease (ASCVD). The 2013 guidelines changed this focus to treating patients with appropriate statin intensity given their ASCVD risk. We examined statin use and LDL-C levels before and after the 2013 ACC/AHA guidelines in patients with clinical ASCVD as defined in the guidelines...
March 17, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28282508/cardiovascular-risk-profile-in-patients-with-myelopathy-associated-with-htlv-1
#8
Fabio Luís Silva do Prado, Renata Prado de Fuccio Oliveira, Ana Marice Teixeira Ladeia
HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis) is a slowly progressive disease, characterized by a chronic spastic paraparesis. It is not known if the disease carries an independent risk for cardiovascular disease. The objective of this study was to evaluate the cardiovascular risk profile related to HAM/TSP and compare it with the general population. METHODS: This was a cross-sectional study, with a control group. HAM/TSP patients were evaluated using cardiovascular risk scores (ASCVD RISK, SCORE and Framingham) and inflammatory markers (ultrasensitive CRP and IL-6), and compared with a control group of healthy individuals...
March 7, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28275165/predicting-cardiovascular-events-in-familial-hypercholesterolemia-the-safeheart-registry
#9
Leopoldo Pérez de Isla, Rodrigo Alonso, Nelva Mata, Cristina Fernández-Pérez, Ovidio Muñiz, José Luis Díaz-Díaz, Adriana Saltijeral, Francisco J Fuentes-Jiménez, Raimundo de Andrés, Daniel Zambón, Mar Piedecausa, José María Cepeda, Marta Mauri, Jesús Galiana, Ángel Brea, Juan F Sanchez Muñoz-Torrero, Teresa Padró, Rosa Argueso, José Pablo Miramontes-González, Lina Badimón, Raúl D Santos, Gerald F Watts, Pedro Mata
Background -Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in familial hypercholesterolaemia (FH) have been described, models for predicting incident ASCVD have not been reported. Our aim was to utilise the SAFEHEART registry to define key risk factors for predicting incident ASCVD in patients with FH. Methods -SAFEHEART is a multicentre, nationwide, long-term prospective cohort study of a molecularly-defined population with FH, with or without previous ASCVD. Analysis to define risk factors and to build a risk prediction equation were developed and tested for its ability to discriminate patients who experience incident ASCVD from those who did not over time...
March 8, 2017: Circulation
https://www.readbyqxmd.com/read/28273386/performance-of-the-pooled-cohort-atherosclerotic-cardiovascular-disease-risk-score-in-hepatitis-c-virus-infected-persons
#10
Kara W Chew, Debika Bhattacharya, Tamara B Horwich, Peng Yan, Kathleen A McGinnis, Chi-Hong Tseng, Matthew S Freiberg, Judith S Currier, Adeel A Butt
Chronic hepatitis C virus (HCV) infection has been associated with an increased risk for cardiovascular disease (CVD). The recommended Pooled Cohort Atherosclerotic Cardiovascular Disease (ASCVD) risk equation for estimation of 10-year CVD risk has not been validated in HCV-infected populations. We examined the performance of the ASCVD risk score in HCV-infected persons, using the national Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to derive a cohort of HCV-infected and uninfected subjects without baseline ASCVD, hepatitis B, or HIV infection, and with low-density lipoprotein cholesterol level<190 mg/dL...
March 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28263370/fixed-dose-combination-therapy-for-the-prevention-of-atherosclerotic-cardiovascular-diseases
#11
REVIEW
Ehete Bahiru, Angharad N de Cates, Matthew Rb Farr, Morag C Jarvis, Mohan Palla, Karen Rees, Shah Ebrahim, Mark D Huffman
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES: To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events...
March 6, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28249067/adoption-of-the-2013-american-college-of-cardiology-american-heart-association-cholesterol-management-guideline-in-cardiology-practices-nationwide
#12
Yashashwi Pokharel, Fengming Tang, Philip G Jones, Vijay Nambi, Vera A Bittner, Ravi S Hira, Khurram Nasir, Paul S Chan, Thomas M Maddox, William J Oetgen, Paul A Heidenreich, William B Borden, John A Spertus, Laura A Petersen, Christie M Ballantyne, Salim S Virani
Importance: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline recommends moderate-intensity to high-intensity statin therapy in eligible patients. Objective: To examine adoption of the 2013 ACC/AHA guideline in US cardiology practices. Design, Setting, and Participants: Among 161 cardiology practices, trends in the use of moderate-intensity to high-intensity statin and nonstatin lipid-lowering therapy (LLT) were analyzed before (September 1, 2012, to November 1, 2013) and after (February 1, 2014, to April 1, 2015) publication of the 2013 ACC/AHA guideline among 4 mutually exclusive risk groups within the ACC Practice Innovation and Clinical Excellence Registry...
March 1, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28247847/risk-estimates-for-atherosclerotic-cardiovascular-disease-in-adults-with-congenital-heart-disease
#13
George K Lui, Ian S Rogers, Victoria Y Ding, Haley K Hedlin, Kirstie MacMillen, David J Maron, Christy Sillman, Anitra Romfh, Tara C Dade, Christiane Haeffele, Stafford R Grady, Doff B McElhinney, Daniel J Murphy, Susan M Fernandes
The adult with congenital heart disease (CHD) is at risk of developing atherosclerotic cardiovascular disease (ASCVD). We performed a cross-sectional study to describe established ASCVD risk factors and estimate 10-year and lifetime risk of ASCVD in adults over age 18 with CHD of moderate or great complexity using 3 validated risk assessment tools-the Framingham Study Cardiovascular Disease Risk Assessment, the Reynolds Risk Score, and the ASCVD Risk Estimator. We obtained extensive clinical and survey data on 178 enrolled patients, with average age 37...
January 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28242176/2017-taiwan-lipid-guidelines-for-high-risk-patients
#14
REVIEW
Yi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, Min-Ji Charng, Tsung-Hsien Lin, Kuo-Liong Chien, Chih-Yuan Wang, Ting-Hsing Chao, Ping-Yen Liu, Cheng-Huang Su, Shih-Chieh Chien, Chia-Wei Liou, Sung-Chun Tang, Chun-Chuan Lee, Tse-Ya Yu, Jaw-Wen Chen, Chau-Chung Wu, Hung-I Yeh
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients...
February 24, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28239070/lipid-lowering-therapy-to-modify-plaque-microstructures
#15
Yu Kataoka, Jordan Andrews, Rishi Puri, Peter Psaltis, Stephen J Nicholls
Due to the pandemics of obesity and diabetes mellitus, especially in the Western countries, atherosclerotic cardiovascular disease (ASCVD) has become a major health burden and is expected to increase in the future. Modifying lipid targets, especially low-density lipoprotein cholesterol (LDL-C) level, has become the first-line therapy for primary and secondary prevention of ASCVD. Intravascular imaging modalities have contributed to elucidating clinical efficacy of lipid lowering therapy on atherosclerotic plaques...
February 24, 2017: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/28213597/retrospective-examination-of-lipid-lowering-treatment-patterns-in-a-real-world-high-risk-cohort-in-the-uk-in-2014-comparison-with-the-national-institute-for-health-and-care-excellence-nice-2014-lipid-modification-guidelines
#16
Dylan L Steen, Irfan Khan, David Ansell, Robert J Sanchez, Kausik K Ray
BACKGROUND: In 2014, guidelines from the National Institute for Health and Care Excellence (NICE) provided updated recommendations on lipid-modifying therapy (LMT). We assessed clinical practice contemporaneous to release of these guidelines in a UK general practice setting for secondary and high-risk primary-prevention populations, and extrapolated the findings to UK nation level. METHODS: Patients from The Health Improvement Network database with the following criteria were included: lipid profile in 2014 (index date); ≥20 years of age; ≥2 years representation in database prior to index; ≥1 statin indication either for atherosclerotic cardiovascular disease (ASCVD) or the non-ASCVD conditions high-risk diabetes mellitus and/or chronic kidney disease...
February 17, 2017: BMJ Open
https://www.readbyqxmd.com/read/28206704/lipid-lowering-efficacy-and-safety-of-alirocumab-in-patients-with-or-without-diabetes-a-sub-analysis-of-odyssey-combo-ii
#17
Lawrence A Leiter, Jose Luis Zamorano, Maja Bujas-Bobanovic, Michael J Louie, Guillaume Lecorps, Christopher P Cannon, Yehuda Handelsman
AIM: This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy. MATERIALS AND METHODS: COMBO II was a 104-week, double-blind study (n = 720) enrolling patients with documented atherosclerotic cardiovascular disease (ASCVD) and baseline LDL-C ≥70 mg/dL (1...
February 16, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28197978/managing-cardiovascular-risk-in-lysosomal-acid-lipase-deficiency
#18
REVIEW
James J Maciejko
Lysosomal acid lipase deficiency (LAL-D) is a rare, life-threatening, autosomal recessive, lysosomal storage disease caused by mutations in the LIPA gene, which encodes for lysosomal acid lipase (LAL). This enzyme is necessary for the hydrolysis of cholesteryl ester and triglyceride in lysosomes. Deficient LAL activity causes accumulation of these lipids in lysosomes and a marked decrease in the cytoplasmic free cholesterol concentration, leading to dysfunctional cholesterol homeostasis. The accumulation of neutral lipid occurs predominantly in liver, spleen, and macrophages throughout the body, and the aberrant cholesterol homeostasis causes a marked dyslipidemia...
February 14, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/28179220/modifiable-risk-factors-versus-age-on-developing-high-predicted-cardiovascular-disease-risk-in-blacks
#19
Adam P Bress, Lisandro D Colantonio, John N Booth, Tanya M Spruill, Joseph Ravenell, Mark Butler, Amanda J Shallcross, Samantha R Seals, Kristi Reynolds, Gbenga Ogedegbe, Daichi Shimbo, Paul Muntner
BACKGROUND: Clinical guidelines recommend using predicted atherosclerotic cardiovascular disease (ASCVD) risk to inform treatment decisions. The objective was to compare the contribution of changes in modifiable risk factors versus aging to the development of high 10-year predicted ASCVD risk. METHODS AND RESULTS: A prospective follow-up was done of the Jackson Heart Study, an exclusively black cohort at visit 1 (2000-2004) and visit 3 (2009-2012). Analyses included 1115 black participants without high 10-year predicted ASCVD risk (<7...
February 8, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28151011/cardiovascular-risk-factors-and-glucose-tolerance-in-midlife-and-risk-of-cognitive-disorders-in-old-age-up-to-a-49-year-follow-up-of-the-helsinki-businessmen-study
#20
Kirsi Rantanen, Arto Y Strandberg, Veikko V Salomaa, Kaisu H Pitkälä, Reijo S Tilvis, Pentti J Tienari, Timo E Strandberg
PURPOSE: To compare midlife predictors of old age dementia with or without concomitant atherosclerotic cardiovascular disease (ASCVD). DESIGN: In the Helsinki Businessmen Study (men born in 1919-1934, n = 3309) death certificates (n = 1885) during up to 49-year follow-up (through December 31, 2013) were screened for dementia (n = 365) and ASCVD, and categorized as 1) AD without ASCVD ("pure" AD, n = 93), 2) AD+ASCVD (n = 126), 3) Vascular dementia (VD, n = 82), 4) Other or undefined etiology (n = 64)...
February 2, 2017: Annals of Medicine
keyword
keyword
67127
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"